Clearing the Signal: Serum Prostate-Specific Antigen Trajectories After Transurethral Resection or Open Simple Prostatectomy Versus Tamsulosin–Dutasteride Therapy in Men With Benign Prostatic Enlargement and a Benign Biopsy — A Secondary Analysis of a 12-Week Prospective Cohort
Health Innovation Reports · 2026
DOI: 10.64048/hir.v2n2.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Innovation Reports, 2026. Verfasst von Jihad Haji Saleh und 2 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and aim: Men with benign prostatic enlargement often have a serum prostate-specific antigen (PSA) above 4 ng/mL, prompting biopsy; when the biopsy is benign, the expected post-treatment PSA fall is uncertain. This study compared 12-week PSA trajectories after transurethral resection of the prostate (TURP) or open simple prostatectomy with those after tamsulosin–dutasteride therapy.
Methods
This secondary analysis used an open, anonymized prospective cohort of 154 men with benign prostatic enlargement, elevated PSA and a benign biopsy from the University of Nigeria Teaching Hospital, Enugu. Total PSA was measured at baseline, 6 and 12 weeks and analysed with mixed analysis of variance, multivariable linear regression and logistic regression.
Results
Among 154 men (77 medical therapy, 43 TURP, 34 open prostatectomy), median baseline PSA was 5.60, 10.00 and 15.80 ng/mL, respectively (p < .001). A significant treatment × time interaction was observed (p < .001): mean 12-week reductions were 56.4%, 77.1% and 83.6%, respectively. After adjustment for baseline PSA and clinical characteristics, TURP (β = 17.12) and open prostatectomy (β = 16.98) were associated with greater reduction than medical therapy (both p < .001; adjusted R² = 0.56). Among surgical patients, higher baseline PSA reduced the odds of PSA < 4.0 ng/mL at week 6 (adjusted OR = 0.59, p < .001), whereas 96.1% had normalized by week 12.
Conclusions
Surgery produced faster and deeper PSA clearance than tamsulosin–dutasteride therapy, independent of baseline PSA. A 12-week PSA check interpreted against treatment-specific expected reductions may guide follow-up.
Zitieren
APA
Saleh, J. H., Rasool, A. A., & Hasan, H. A. (2026). Clearing the Signal: Serum Prostate-Specific Antigen Trajectories After Transurethral Resection or Open Simple Prostatectomy Versus Tamsulosin–Dutasteride Therapy in Men With Benign Prostatic Enlargement and a Benign Biopsy — A Secondary Analysis of a 12-Week Prospective Cohort. Health Innovation Reports. https://doi.org/10.64048/hir.v2n2.003
Vancouver
Saleh JH, Rasool AA, Hasan HA. Clearing the Signal: Serum Prostate-Specific Antigen Trajectories After Transurethral Resection or Open Simple Prostatectomy Versus Tamsulosin–Dutasteride Therapy in Men With Benign Prostatic Enlargement and a Benign Biopsy — A Secondary Analysis of a 12-Week Prospective Cohort. Health Innovation Reports. 2026. doi:10.64048/hir.v2n2.003
BibTeX
@article{Saleh2026,
author = {Saleh, Jihad Haji and Rasool, Abdulqadr Abdulrahman and Hasan, Hardi Abdulqadir},
title = {Clearing the Signal: Serum Prostate-Specific Antigen Trajectories After Transurethral Resection or Open Simple Prostatectomy Versus Tamsulosin–Dutasteride Therapy in Men With Benign Prostatic Enlargement and a Benign Biopsy — A Secondary Analysis of a 12-Week Prospective Cohort},
journal = {Health Innovation Reports},
year = {2026},
doi = {10.64048/hir.v2n2.003}
}
EUVIMED